Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy

University of Campania "Luigi Vanvitelli"

Status and phase: Completed; Phase 4

Conditions: Proliferative Diabetic Retinopathy

Treatments: Drug: Bevacizumab; Other: sham

Study type: Interventional

Funder types: Other

Identifiers

NCT01025934

IVBDRNA

Details and patient eligibility

About

The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• vitreous haemorrhage
• tractional retinal detachment
• active proliferative diabetic retinopathy.

Exclusion criteria

• neovascular glaucoma
• cataract
• combined traction and rhegmatogenous RD

Trial design

0 participants in 3 patient groups

7 days

Active Comparator group

Treatment:

Drug: Bevacizumab

20 days

Active Comparator group

Treatment:

Drug: Bevacizumab

sham

Sham Comparator group

Treatment:

Other: sham